SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections